VIVUS Announces Positive Phase 3 Clinical Trial Results For Evamist(TM) - The First Transdermal Spray For The Treatment Of Menopausal Symptoms

... VIVUS, Inc.(Nasdaq: VVUS) today announced positive results from the pivotal Phase 3clinical trial of Evamist(TM). VIVUS' investigational estradiol metereddose transdermal spray is being developed for the treatment of vasomotorsymptoms associated with menopause. The study showed a statisticallysignificant reduction in the number and severity of moderate and severe hotflashes for all three doses tested... click link for more info. ...